https://www.selleckchem.com/products/k03861.html MiR-326 overexpression markedly restrained the proliferation and invasion of OC cells, whereas miR-326 inhibitors exerted the contrary effect. Additionally, miR-326 up-regulation in OC cells prevented cells from entering S-phase and enhanced apoptosis, a phenomenon that may be due to CDCA5 down-regulation. Furthermore, we proved that CDCA5 was a downstream target of miR-326. MiR-326 represses the proliferation and invasion of OC cells and enhances apoptosis by specifically modulating CDCA5 expression. MiR-326 represses the proliferation and invasion of OC cells and enhances apoptosis by specifically modulating CDCA5 expression. Despite many known risk factors for the colorectal cancer (CRC) recurrence, significant differences in disease-free survival (DFS) impose the need to look for new explanations. This study aimed to determine the degree of expression of ERα, ERβ, PR, Cyclin D1, and Bcl-2 and their association with early CRC relapse. This retrospective study included 101 radically operated CRC patients in high-risk Duke's B and Duke's C stage. Tissue samples were retrieved from paraffin blocks and clinical and diagnostic data from medical records obtained during further clinical treatment and follow up. Patients were divided into DFS≤24 months group and DFS≥48 months group. Immunostaining of ERα, ERβ, PR, Cyclin D1, and Bcl-2 was performed and analyzed. ERα was not expressed in all patients. ERβ moderate expression was present in 25% of all patients, more often in the DFS≥48 group (p=0.001). PR and Bcl-2 showed only moderate expression in 1/5 and 1/3 of the patients, respectively, without significant difference between groups (p=0.145;p=0.566). Cyclin D1 was expressed in the whole sample of patients with strong expression statistically more often in DFS≤24 group (p=0.011) and had 5.2 higher odds of having DFS˂24 months. Moderate expression of ERβ was joined with 79.2% smaller odds for shorter DFS. Advanced T stage